58501NAA9
Medivation Inc
Could not find a ticker for this position, may be a filing error
A San Francisco biopharmaceutical company that develops medicines for serious illnesses, best known for Xtandi (enzalutamide), an oral prostate cancer drug it co-developed and marketed with Japan's Astellas. Oncologist David Hung and investor Steve Gorlin founded the firm in 2003, after Hung—moved by a young breast cancer patient's death during his fellowship—resolved to do something about such diseases. Its name blends "medical" and "innovation." In 2016 Pfizer bought the company and absorbed it.
CONVERTIBLEUnderlying: MDVNCUSIP: 58501NAA9HealthcareUS1 derivative reporter
2.625% Convertible Senior Notes due April 1, 2017
No tracked superinvestor held this security as stock in this period — only the derivative positions below reference it.
Derivative Reporters
Investor
Kind
13F reported value
Quantity
Change
